Archetypes of checkpoint-responsive immunity.

Trends Immunol

Department of Pathology and ImmunoX Initiative, University of California at San Francisco, San Francisco, CA 94143, USA. Electronic address:

Published: November 2021

Responsiveness to immune checkpoint blockade (ICB) therapy in cancer is currently predicted by disparate individual measures - with varying degrees of accuracy - including tumor mutation burden, tumor-infiltrating T cell densities, dendritic cell frequencies, and the expression of checkpoint ligands. We propose that many of these individual parameters are linked, forming two distinct 'reactive' immune archetypes - collections of cells and gene expression - in ICB-responsive patients. We hypothesize that these are 'seeds' of antitumor immunity and are supported by specific elements of the tumor microenvironment (TME) and by actions of the microbiome. Although removing 'immunosuppressive' factors in the TME is important, understanding and parsing reactive immunity is crucial for optimal prognosis and for engaging this biology with candidate therapies to increase tumor cure rates.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724347PMC
http://dx.doi.org/10.1016/j.it.2021.09.007DOI Listing

Publication Analysis

Top Keywords

archetypes checkpoint-responsive
4
checkpoint-responsive immunity
4
immunity responsiveness
4
responsiveness immune
4
immune checkpoint
4
checkpoint blockade
4
blockade icb
4
icb therapy
4
therapy cancer
4
cancer currently
4

Similar Publications

Archetypes of checkpoint-responsive immunity.

Trends Immunol

November 2021

Department of Pathology and ImmunoX Initiative, University of California at San Francisco, San Francisco, CA 94143, USA. Electronic address:

Responsiveness to immune checkpoint blockade (ICB) therapy in cancer is currently predicted by disparate individual measures - with varying degrees of accuracy - including tumor mutation burden, tumor-infiltrating T cell densities, dendritic cell frequencies, and the expression of checkpoint ligands. We propose that many of these individual parameters are linked, forming two distinct 'reactive' immune archetypes - collections of cells and gene expression - in ICB-responsive patients. We hypothesize that these are 'seeds' of antitumor immunity and are supported by specific elements of the tumor microenvironment (TME) and by actions of the microbiome.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!